| Identification | Back Directory | [Name]
IMB-808 | [CAS]
870768-70-0 | [Synonyms]
IMB-808
1,4-Benzodioxin-6-carboxamide, 2,3-dihydro-N-methyl-N-[2-oxo-2-[(2,3,4-trifluorophenyl)amino]ethyl]- | [Molecular Formula]
C18H15F3N2O4 | [MDL Number]
MFCD07342695 | [MOL File]
870768-70-0.mol | [Molecular Weight]
380.32 |
| Chemical Properties | Back Directory | [storage temp. ]
2-8°C | [solubility ]
DMSO: 2mg/mL, clear | [form ]
Solid | [color ]
White to off-white | [InChI]
1S/C18H15F3N2O4/c1-23(9-15(24)22-12-4-3-11(19)16(20)17(12)21)18(25)10-2-5-13-14(8-10)27-7-6-26-13/h2-5,8H,6-7,9H2,1H3,(H,22,24) | [InChIKey]
XITZPIXICJOKTF-UHFFFAOYSA-N | [SMILES]
FC1=C(NC(CN(C)C(C2=CC(OCCO3)=C3C=C2)=O)=O)C=CC(F)=C1F |
| Hazard Information | Back Directory | [Description]
IMB-808 is a potent liver X receptor α and β (LXRα/β) partial dual agonist that promotes expression of genes related to reverse cholesterol transport (including ABCA1 and ABCG1). | [Uses]
IMB-808 is a potent LXRα/β dual agonist with EC50 values of 0.53 μM and 0.15 μM (0.15 μM, using GAL4-pGL4-luc reporter plasmid) for LXRβ and LXRα, respectively. IMB-808 promotes expression of genes related to reverse cholesterol transport (ABCA1 and ABCG1). IMB-808 can be used as a promising agent for the prospective treatment of atherosclerosis research[1]. | [References]
[1] Duo Lu, et al. Identification of a Novel Liver X Receptor Agonist that Regulates the Expression of Key Cholesterol Homeostasis Genes with Distinct Pharmacological Characteristics. Mol Pharmacol. 2017 Apr;91(4):264-276. DOI:10.1124/mol.116.105213 |
|
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
|